These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 36279753)

  • 1. Intrasubject subcortical quantitative referencing to boost MRI sensitivity to Parkinson's disease.
    Khedher L; Bonny JM; Marques A; Durand E; Pereira B; Chupin M; Vidal T; Chassain C; Defebvre L; Carriere N; Fraix V; Moro E; Thobois S; Metereau E; Mangone G; Vidailhet M; Corvol JC; Lehéricy S; Menjot de Champfleur N; Geny C; Spampinato U; Meissner W; Frismand S; Schmitt E; Doé de Maindreville A; Portefaix C; Remy P; Fénelon G; Luc Houeto J; Colin O; Rascol O; Peran P; Durif F;
    Neuroimage Clin; 2022; 36():103231. PubMed ID: 36279753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantifying iron deposition within the substantia nigra of Parkinson's disease by quantitative susceptibility mapping.
    An H; Zeng X; Niu T; Li G; Yang J; Zheng L; Zhou W; Liu H; Zhang M; Huang D; Li J
    J Neurol Sci; 2018 Mar; 386():46-52. PubMed ID: 29406966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative Susceptibility Mapping in Parkinson's Disease.
    Langkammer C; Pirpamer L; Seiler S; Deistung A; Schweser F; Franthal S; Homayoon N; Katschnig-Winter P; Koegl-Wallner M; Pendl T; Stoegerer EM; Wenzel K; Fazekas F; Ropele S; Reichenbach JR; Schmidt R; Schwingenschuh P
    PLoS One; 2016; 11(9):e0162460. PubMed ID: 27598250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Region-specific disturbed iron distribution in early idiopathic Parkinson's disease measured by quantitative susceptibility mapping.
    He N; Ling H; Ding B; Huang J; Zhang Y; Zhang Z; Liu C; Chen K; Yan F
    Hum Brain Mapp; 2015 Nov; 36(11):4407-20. PubMed ID: 26249218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease.
    Jin L; Wang J; Zhao L; Jin H; Fei G; Zhang Y; Zeng M; Zhong C
    Brain; 2011 Jan; 134(Pt 1):50-8. PubMed ID: 21109502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct progression pattern of susceptibility MRI in the substantia nigra of Parkinson's patients.
    Du G; Lewis MM; Sica C; He L; Connor JR; Kong L; Mailman RB; Huang X
    Mov Disord; 2018 Sep; 33(9):1423-1431. PubMed ID: 29756399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential Effect of Iron and Myelin on Susceptibility MRI in the Substantia Nigra.
    Lee H; Cho H; Lee MJ; Kim TH; Roh J; Lee JH
    Radiology; 2021 Dec; 301(3):682-691. PubMed ID: 34609198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of freezing of gait with nigral iron accumulation in patients with Parkinson's disease.
    Naduthota RM; Honnedevasthana AA; Lenka A; Saini J; Geethanath S; Bharath RD; Christopher R; Yadav R; Gupta AK; Pal PK
    J Neurol Sci; 2017 Nov; 382():61-65. PubMed ID: 29111022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of QSM over R2* in assessment of parkinson's disease - A systematic review.
    Saikiran P;
    Neurol India; 2020; 68(2):278-281. PubMed ID: 32415005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased iron in the substantia nigra pars compacta identifies patients with early Parkinson'sdisease: A 3T and 7T MRI study.
    Alushaj E; Handfield-Jones N; Kuurstra A; Morava A; Menon RS; Owen AM; Sharma M; Khan AR; MacDonald PA
    Neuroimage Clin; 2024; 41():103577. PubMed ID: 38377722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective R
    Luo J; Collingwood JF
    J Neurosci Methods; 2022 Dec; 382():109708. PubMed ID: 36089168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Automated volumetric determination of high R
    Tessema AW; Lee H; Gong Y; Cho H; Adem HM; Lyu I; Lee JH; Cho H
    NMR Biomed; 2022 Nov; 35(11):e4795. PubMed ID: 35775868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extra-basal ganglia iron content and non-motor symptoms in drug-naïve, early Parkinson's disease.
    Kim M; Yoo S; Kim D; Cho JW; Kim JS; Ahn JH; Mun JK; Choi I; Lee SK; Youn J
    Neurol Sci; 2021 Dec; 42(12):5297-5304. PubMed ID: 33860863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application value of multiparametric MRI for evaluating iron deposition in the substantia nigra in Parkinson's disease.
    Cao Q; Huang J; Tang D; Qian H; Yan K; Shi X; Li Y; Zhang J
    Front Neurol; 2022; 13():1096966. PubMed ID: 36686531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring Substantia Nigra Degeneration Using Free Water Imaging across Prodromal and Clinical Parkinson's Disease.
    Zhou G; Ren J; Rong D; Zhou H; Ning H; Wang H; Pan C; Wang Y; Zhang R; Guo Z; Huang P; Liu W
    Mov Disord; 2023 May; 38(5):774-782. PubMed ID: 36947674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parkinson's disease related signal change in the nigrosomes 1-5 and the substantia nigra using T2* weighted 7T MRI.
    Schwarz ST; Mougin O; Xing Y; Blazejewska A; Bajaj N; Auer DP; Gowland P
    Neuroimage Clin; 2018; 19():683-689. PubMed ID: 29872633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regionally progressive accumulation of iron in Parkinson's disease as measured by quantitative susceptibility mapping.
    Guan X; Xuan M; Gu Q; Huang P; Liu C; Wang N; Xu X; Luo W; Zhang M
    NMR Biomed; 2017 Apr; 30(4):. PubMed ID: 26853890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative evaluation of brain iron accumulation in different stages of Parkinson's disease.
    Li KR; Avecillas-Chasin J; Nguyen TD; Gillen KM; Dimov A; Chang E; Skudin C; Kopell BH; Wang Y; Shtilbans A
    J Neuroimaging; 2022 Mar; 32(2):363-371. PubMed ID: 34904328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased iron-deposition in lateral-ventral substantia nigra pars compacta: A promising neuroimaging marker for Parkinson's disease.
    He N; Langley J; Huddleston DE; Chen S; Huang P; Ling H; Yan F; Hu X
    Neuroimage Clin; 2020; 28():102391. PubMed ID: 32889398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum cholesterol and nigrostriatal R2* values in Parkinson's disease.
    Du G; Lewis MM; Shaffer ML; Chen H; Yang QX; Mailman RB; Huang X
    PLoS One; 2012; 7(4):e35397. PubMed ID: 22530017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.